eligibility_summary
Adults 18–70 with untreated primary oral SCC (buccal, gum, tongue, floor), no mandibular invasion but needs segmental mandibulectomy, AJCC T3–4N0–3M0 (III–IVb), PS 0–1, resectable, ≥1 RECIST lesion, adequate marrow/liver/renal/coag/thyroid, contraception/negative pregnancy test. Exclude: mAb/PD‑1 allergy, autoimmune or seizure disorders, inoperable/new mets, coagulopathy/bleeding, severe cardiac/pulmonary disease, prior ICI/investigational drug/immunosuppression/live vaccine, recent major surgery/trauma/serious infection, HIV, active HBV/HCV, other recent cancer, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-arm phase II neoadjuvant trial in resectable, locally advanced oral squamous cell carcinoma testing: 1) Tislelizumab—anti–PD-1 monoclonal antibody immunotherapy, 2) Platinum–taxane chemotherapy (cisplatin/carboplatin plus paclitaxel or docetaxel), cytotoxic agents. Mechanisms: Tislelizumab blocks the PD-1/PD-L1 checkpoint to restore cytotoxic T-cell function, platinum agents create DNA crosslinks leading to apoptosis, taxanes stabilize microtubules, causing mitotic arrest. Targets/pathways: PD-1 on T cells and the PD-1/PD-L1 axis, tumor cell DNA damage response via platinum-induced crosslinking, microtubule dynamics in proliferating tumor cells. Goal: tumor shrinkage pre-surgery to increase mandibular preservation.